Inflammation from ADT may cause fatigue in prostate cancer patients

Prostate cancer is one of the most common cancers among men in the US. For many patients, hormone therapy is a treatment option. This type of therapy, also called androgen deprivation therapy (ADT), reduces the level of testosterone and other androgens in the body. Lowering androgen levels can make prostate cancer cells grow more slowly or shrink tumors over time. However, patients receiving ADT often experience higher levels of fatigue, depression and cognitive impairment.

Latest News

Related articles